Therapy Trends KOL Insight: Pancreatic Cancer [2019]

Maximum Purchase:
1 unit
Publication Date:
February 2019
Adding to cart… The item has been added

Are innovative modalities set to transform pancreatic cancer?

Pancreatic cancer (PC) is widely regarded as the world's most lethal malignancy. Though outcomes have improved modestly with resection and adjuvant radiotherapy in combination with chemotherapy, treatment continues to be a challenging prospect. However, novel small-molecule and biologic modalities are emerging through the late-stage development, but in a difficult to treat malignancy which candidates will stand out? Want to find out more?

Learn how KOLs see the pancreatic cancer market evolving in Therapy Trends KOL Insight: Pancreatic Cancer. Eleven US and European KOLs provide candid insightson 3marketed and 14 pipeline therapies targeting various aspects of the PC treatment algorithm.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • What do KOLs consider to be the major unmet needs for PC? What are the major challenges and how effective are the current modalities for treating the malignancy?
  • How do KOLs expect the small molecule targeted approaches to fare in PC? Can Pharmacyclics/Janssen’s Imbruvica and AstraZeneca/Merck & Co.’s Lynparza play an effective role?
  • Will immuno-oncology therapies make an impact in PC? ARMO/Eli Lilly’s pegylated formulation of rhIL-10, ilodecakin and InnoMab’s nimotuzumab, an EGFR antibody are in Phase III but how do KOLs rate their potential?
  • FibroGen’s pamrevlumab, a humanised mAb that inhibits the activity of connective tissue growth factor (CTGF), is expected to move into Phase III shortly. Do experts see a role for the antibody in PC?
  • What do KOLs think of the potential of checkpoint inhibitors in PC? PD-1/PD-L1 and CTLA-4 inhibitors are being trialled in PC but, according to KOLs what products standout and why?
  • Can vaccine/immunostimulants provide the much-needed breakthrough for PC? How do KOLs view the prospects of Bavarian Nordic/BMS’s PANVAC (CV301), ERYtech Pharma‘s GRASPA and Boston Biomedical’s napabucasin?
  • How do KOLs view Halozyme/Nektar’s pegvorhyaluronidase alfa? Can the Phase III HALO-301 study in combination with nab-paclitaxel plus gemcitabine for the agent deliver positive data?
  • What recommendations do KOLs have for companies developing PC therapies? What should they be doing in expedite the delivery of effective modalities?
Request sample pages

Back to the top


“The first line is surgery, but that's effective in 5 to 10 percent of patients. Most patients are diagnosed at an advanced stage. Even surgery is not considered, because they're metastatic. Apart from chemotherapy, there are no effective treatments for patients with advanced disease.”
US Key Opinion Leader

“The therapeutic agents we currently have are far from adequate, and still remain almost fully in the realm of standard toxic chemotherapy agents rather than targeted agents or immunotherapies that are transforming other cancer types. PC is a little bit left behind as far as that goes.”
US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Tarceva (Astellas Pharma/Chugai Pharmaceutical/Roche)
  • Keytruda (Merck & Co.)
  • Riavax (KAEL-GemVax/Samsung)

Pipeline Therapies

  • Algenpantucel-L (NewLink Genetics)
  • GRASPA (ERYtech Pharma)
  • Ibrutinib (Pharmacyclics/Janssen)
  • Ilodecakin (ARMO Biosciences/Eli Lilly)
  • Imfinzi (MedImmune/AstraZeneca)
  • Napabucasin (Boston Biomedical)
  • Nimotuzumab (InnoMab)
  • Olaparib (AstraZeneca/Merck & Co.)
  • Olaparib companion diagnostic (Myriad Genetics)
  • Opdivo (Bristol-Myers Squibb/Ono Pharmaceuticals)
  • Pamrevlumab (FibroGen)
  • Panvac (CV301) Bavarian Nordic/Bristol-Myers Squibb
  • Pegvorhyaluronidase alfa (PEGPH20; Halozyme Therapeutics/Nektar Therapeutics)
  • Yervoy (Bristol-Myers Squibb)

KOLs interviewed

KOLs from North America

  • Andrew Ko MD, Medical Oncologist, Professor, Helen Diller Family Comprehensive Cancer Center, Department of Medicine (Hematology/Oncology), UCSF, San Francisco, CA
  • Benjamin L. Musher MD, Medical oncologist, Associate Professor, Division of Hematology-Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
  • Eric Rowinsky MD,Oncology specialist, Adjunct Professor of Medicine, Department of Oncology, New York School of Medicine. New York University. NY
  • Michael Aaron Morse MD, FACP, MHS, Medical Oncologist, Professor of Medicine, Duke Cancer Institute, Duke University School of Medicine, Durham, NC
  • Nevena Damjanov, MD, Chief Hematology/Oncology, Professor of Clinical Medicine, Penn Presbyterian Medical Center, Penn Medicne, University of Pennsylvania, Philadelphia, PA
  • Jill Lacy MDMedical Oncologist, Professor of Medicine (Medical Oncology), Yale School of Medicine, Yale New Haven Hospital, New Haven, CT

KOLs from Europe

  • Anonymous German KOL, Prof. Dr., Professor of Medicine (Medical Oncology) and Director at a teaching hospital in Germany
  • Anonymous German KOL, Prof. Dr., Oncology Specialist and Professor of Medicine (Medical Oncology) at a teaching hospital in Germa
  • Antonieta Salud-Salvia MD, Medical oncologist, Professor, Medical Oncology Department, University Hospital Arnau de Vilanova, Lleida, Spain
  • Debashis Sarker MBChB, PhD, Medical Oncologust,  Consultant & Senior Lecturer in Medical Oncology, Guy's, St Thomas' and King's College Hospitals, Kings College London, United Kingdom
  • Khurum Khan MBBS, MD, MRCP, Medical Oncologist, Consultant, Department of Medicine, The Royal Marsden NHS Trust, The Institute of Cancer Research, London, United Kingdom

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.